EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer

Mengqing Chen, Lin Huang, Mengna Zhu, Jing Cai, Feiquan Ying, Lin Liu, Wenhan Li, Si Sun, Yiping Wen

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04215-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Mengqing Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuh…. Hauptthemen laut MEDLINE: Checkpoint Kinase 1, Neoplastic Stem Cells, Ovarian Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cancer stem cells (CSCs) are considered the 'seeds' of recurrence after chemotherapy, but eliminating CSCs remains notoriously challenging. This study aims to examine whether cell cycle checkpoint kinase 1 (CHK1) blockade can abrogate the stemness of ovarian cancer (OC) cells, making them easier targets of anti-tumor immunity. METHODS: Prexasertib was used to block CHK1 in OC cell lines and xenografts, and its cytotoxicity was assessed in vitro and in vivo. In vitro tumor-sphere formation assays and stemness markers were used to evaluate cell stemness. PD-L1 expressions were examined via qRT-PCR, Western blot, flow cytometry, and immunohistochemistry. Prexasertib in combination with anti-PD-L1 antibody Atezolizumab was tested in immune-proficient mice bearing OC xenografts in terms of effects on tumor growth, tumor cell stemness, and tumor infiltrating lymphocytes via tumor volume monitoring, immunohistochemistry, and flow cytometry. RESULTS: Prexasertib effectively inhibited CHK1 phosphorylation, exhibited significant anti-tumor effects in vitro and in vivo, accompanied by decreased OC cell stemness. CHK1 was highly expressed in tumor spheres versus tumor cells cultured in 2D system, and Prexasertib treatment suppressed sphere formation and reduced the ALDH+ cell fraction. Unexpectedly, Prexasertib upregulated PD-L1 expression in tumor cells. In vivo, combining Prexasertib with Atezolizumab led to more remarkable remission of tumors, when compared with Prexasertib or Atezolizumab alone. Meanwhile, the tumor-infiltrating CD8+ T cells significantly increased in the combination group, while exhausted T cells decreased; the treatments did not affect CD4+ cell infiltration. CONCLUSION: Dual targeting of CHK1 and PD-L1 may improve OC treatment by simultaneously suppressing stemness and enhancing anti-tumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Checkpoint Kinase 1Neoplastic Stem CellsOvarian NeoplasmsB7-H1 AntigenPyrazinesPyrazolesAntineoplastic Combined Chemotherapy ProtocolsFemaleAnimalsHumansMiceXenograft Model Antitumor AssaysAntibodies, Monoclonal, HumanizedCell Line, TumorImmune Checkpoint InhibitorsLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

AtezolizumabCancer stem cellsImmune checkpoint proteinsPrexasertib

Substanzen

Checkpoint Kinase 1B7-H1 AntigenprexasertibCHEK1 protein, humanCD274 protein, humanAntibodies, Monoclonal, HumanizedatezolizumabPyrazinesPyrazolesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan, 430022, Hubei, China.
  • Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan, 430022, Hubei, China. sisun@hust.edu.cn.
  • Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan, 430022, Hubei, China. sophiewenyiping@163.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, M., Huang, L., Zhu, M., Cai, J., Ying, F., Liu, L., Li, W., Sun, S., & Wen, Y. (2025). Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04215-9

Vancouver

Chen M, Huang L, Zhu M, Cai J, Ying F, Liu L, et al. Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04215-9

BibTeX
@article{Chen2025,
  author = {Chen, Mengqing and Huang, Lin and Zhu, Mengna and Cai, Jing and Ying, Feiquan and Liu, Lin and Li, Wenhan and Sun, Si and Wen, Yiping},
  title = {Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04215-9}
}
Kostenlos starten →